Preliminary study results presented at the 2026 Military Health System Research Symposium (MHSRS) show reductions in evacuation and surgical treatment times in combat medical settings.
MEDIA, Pa., Sept. 29, 2026 /PRNewswire-PRWeb/ -- InfraScan, Inc., a medical device company specializing in portable brain injury assessment technology, announced the completion of the 600-patient study in Ukraine, evaluating the use of the Infrascanner® handheld brain hemorrhage detection system in the care and triage of patients with traumatic brain injury (TBI).
Results from the study were analyzed and presented at the Military Health System Research Symposium in August 2026.
The study consisted of an initial 300-patient baseline phase followed by a 300-patient device phase completed in April 2026. Of the patients evaluated during the device phase, 200 were treated in austere, forward medical settings.
The results demonstrated significant potential for the Infrascanner to provide decision support for the diagnosis/screening of traumatic brain injuries in environments where access to CT imaging, neurosurgery and rapid medical evacuation may be limited.
Among the key findings presented:
- Evacuation times were reduced (25 minutes – 2 hours) when the Infrascanner was used.
- Use of the Infrascanner was associated with a 47% reduction in time to surgery.
- The device demonstrated 100% sensitivity among patients who ultimately required neurosurgery.
- The vast majority of participating clinicians (88.5%) reported that the Infrascanner contributed to a change in patient care.
- Survey respondents unanimously agreed that the technology was needed at stabilization points and forward surgical teams.
- In polytrauma patients, the Infrascanner served as an adjunctive screening tool and alerted clinicians to abnormalities that developed later or had not been identified during earlier examinations.
- Investigators also reported Infrascanner abnormalities associated with structural head injuries, including penetrating traumatic brain injury, retained fragments and skull fractures, in some cases where intracranial bleeding was not the initial finding.
- The study systems operated throughout the seven-month device phase, including winter field conditions, without reported device failures.
"These results demonstrate why rapid, portable brain assessment can be so important in combat and other austere medical environments," said Baruch Ben Dor, PhD, Chief Executive Officer of InfraScan, Inc. "When CT imaging and neurosurgical care may be hours away, providing clinicians with additional objective information at the point of care can help them make critical triage and evacuation decisions."
The Infrascanner is a handheld screening device utilizing near-infrared technology to assist in identifying intracranial bleeding following head trauma. Unlike CT imaging, the system is portable and can be used in forward medical environments, allowing TBI assessment to begin closer to the point of injury.
The findings are particularly relevant to large scale combat operations, where medical teams may face prolonged evacuation times, limited transportation resources and delayed access to advanced diagnostic imaging.
About the Infrascanner 2500
The Infrascanner 2500 is a portable screening device that uses near-infrared technology to help clinicians identify intracranial bleeding in patients with head trauma. Clinicians can complete a patient assessment within minutes, providing risk-stratification and decision-support information that may help them determine which patients require further evaluation, CT imaging, or escalation to a higher level of care.
About InfraScan, Inc.
InfraScan, Inc. is a medical device company that develops, commercializes, markets, and distributes portable brain scanners for head injury assessment based on near-infrared technology. Infrascanner technology has been developed with support from the U.S. military and has been used in civilian and military medical settings in the United States and internationally.
For more information, visit infrascanner.com.
This effort was awarded through MTEC solicitation MTEC-24-01-MPAI and is funded by the DoD Combat Casualty Research Program (CCCRP) in accordance with the Congressional direction to establish military medical partnerships with the Ukraine specified in NDAA 2023 and 2024. To date, the CCCRP has funded research projects within Ukraine related to traumatic brain injury, hemorrhage control, traumatic stress, rehabilitation, wound management, severe sepsis, and trauma registry development. The DoD CCCRP seeks to develop requirements driven knowledge and material solutions in for the care of combat related traumatic injury during current and future conflicts. The views and conclusions contained herein are those of the author(s) and should not be interpreted as representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
Media Contact
David Clarke, InfraScan, Inc., 1 (603) 566-5149, [email protected], https://infrascanner.com/
SOURCE InfraScan, Inc.
Share this article